+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Amyloidosis - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762938
  • Report
  • 100 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • ADRx Inc
  • Amgen Inc
  • Caelum Biosciences Inc
  • Corino Therapeutics Inc
  • Johnson & Johnson
  • Oncopeptides AB
  • MORE
Summary

Amyloidosis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Amyloidosis R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Amyloidosis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Amyloidosis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Amyloidosis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Amyloidosis pipeline Profiled in detail

Key players actively participating in Amyloidosis pipeline are profiled along with their R&D progress in Amyloidosis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Amyloidosis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Amyloidosis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Amyloidosis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Amyloidosis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Amyloidosis pipeline study
  • All recent news and developments related to Amyloidosis drugs are provided
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ADRx Inc
  • Amgen Inc
  • Caelum Biosciences Inc
  • Corino Therapeutics Inc
  • Johnson & Johnson
  • Oncopeptides AB
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Amyloidosis Disease Overview

3. Amyloidosis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Amyloidosis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Amyloidosis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Amyloidosis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Amyloidosis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ADRx Inc
  • Akcea Therapeutics Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Auven Therapeutics Development Switzerland Sarl
  • BSIM Therapeutics
  • Caelum Biosciences Inc
  • Celgene Corp
  • Chugai Pharmaceutical Co Ltd
  • Corino Therapeutics Inc
  • Eidos Therapeutics Inc
  • IRCCS Policlinico San Matteo
  • Johnson & Johnson
  • Millennium Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Oncopeptides AB
  • Pfizer Inc
  • Proclara Biosciences Inc
  • Prothena Corp Plc
  • R Pharm
  • Regeneron Pharmaceuticals Inc
  • Spectrum Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4762938
Adroll
adroll